乌比基特异性酶11倒置通过调节线粒体功能障碍和神经元损伤来减缓亨廷顿病的进展,这取决于PTEN介导的AKT通路
Bai Gao1, Yuchen Jing2, Xi Li2
1Department of Neurology, Shengjing Hospital of China Medical University, Shenyang, China.
Molecular medicine (Cambridge, Mass.)
|January 8, 2025
概括
沉默USP11通过恢复线粒体功能和通过PTEN抑制激活AKT通路来缓解亨廷顿病 (HD) 病理. 这表明USP11可能是HD的潜在治疗点.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 遗传学 遗传学是一种遗传学.
背景情况:
- 亨廷顿氏病 (HD) 的特征是线粒体功能障碍和神经元损伤.
- 乌比基特异性酶11 (USP11),一种二基化酶,在疾病发病过程中没有明确的作用.
研究的目的:
- 研究USP11在亨廷顿病中的作用.
- 探索USP11作为对HD的潜在治疗点.
主要方法:
- 使用具有USP11特异性的shRNA的腺相关病毒 (AAV) 在R6/1高发症模型小鼠和PC12细胞中用于使USP11沉默.
- 使用无标签蛋白质组学和共免疫沉 (Co-IP) 来确定USP11的目标和相互作用.
- 在体外和体外模型被用来评估USP11敲击对HD病理学的影响.
主要成果:
- 在R6/1小鼠的条纹体中,USP11表达因年龄而上调.
- 在HD模型中,USP11沉默改善了运动活动,空间记忆,减少了条状缩,并恢复了线粒体功能.
- USP11的淘汰促进了PTEN的无化,激活了AKT通路,PTEN的过度表达逆转了这些效应.
结论:
- 通过抑制PTEN和激活AKT通路,USP11 Knockdown保护神经元免受氧化应激,并减轻HD的进展.
- USP11-PTEN-AKT信号通路代表了亨廷顿病的新型治疗点.
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K


